Johnson & Johnson $JNJ Stock Holdings Lifted by Ellsworth Advisors LLC

Key Points

• Ellsworth Advisors LLC increased its holdings in Johnson & Johnson by 3.4%, now owning 44,617 shares worth approximately $7.4 million, making it the firm's 5th largest position.
• Several institutional investors, including Highline Wealth Partners LLC, increased their stakes significantly, with Highline raising its position by 51.8% during the same quarter.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, offering an annual yield of 3.0%, as the company projects an EPS of 10.58 for the current fiscal year.

Ellsworth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 44,617 shares of the company's stock after acquiring an additional 1,450 shares during the quarter. Johnson & Johnson comprises approximately 1.9% of Ellsworth Advisors LLC's holdings, making the stock its 5th largest position. Ellsworth Advisors LLC's holdings in Johnson & Johnson were worth $7,399,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after acquiring an additional 1,170,120 shares during the period. Northern Trust Corp raised its stake in shares of Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after buying an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after buying an additional 448,666 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.2%

NYSE:JNJ traded down $0.40 during trading hours on Friday, hitting $178.10. 7,220,047 shares of the company's stock traded hands, compared to its average volume of 7,548,205. The firm has a market cap of $428.93 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock's fifty day moving average price is $170.81 and its two-hundred day moving average price is $161.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on JNJ shares. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Guggenheim reaffirmed a "neutral" rating and set a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Citigroup boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.